Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
_256_384.jpg)
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023
Subscribe To Our Newsletter & Stay Updated
